| drug name | Alprostadil |
| drug form | | 1 | injection | | 2 | urethral suppository |
|
| patient profile | |
| classification | Vasodilator, Phosphodiesterase inhibitor |
| pharmacokinetics | Alprostadil's effects are primarily localized to the corpus cavernosum. Following injection, it rapidly induces vasodilation. The exact pharmacokinetic profile varies depending on the route of administration (injection vs. suppository). There is a significant first-pass effect in the case of intravenous administration, making it less common. Generally, the effect is localized and short-lived, often within 15-20 minutes for injection, and somewhat longer for suppositories, depending on the specific formulation. Metabolism occurs primarily via the local tissues and degradation products are largely not systemically distributed. |
| suggested dosage | | injection | Variable, individualized and adjusted to patient response. Usually start with a low dose (e.g., 2.5mcg) and titrate to achieve optimal erection. Consult with a healthcare professional for specific dosing instructions. | | suppository | Variable, individualized and adjusted to patient response. Generally, one suppository is used and the dose is titrated to response by adjusting the frequency of use, consult with a healthcare professional for specific dosing instructions. |
|
| indications | Erectile dysfunction (ED), primarily when other treatments are ineffective or not tolerated. |
| safety pregnancy | Contraindicated. Alprostadil is not suitable for use during pregnancy. It may cause adverse effects on the fetus. |
| safety breastfeeding | Alprostadil is not recommended during breastfeeding, as its effects on the infant are unknown. |
| side effects | | 1 | Penis pain or discomfort (at the injection site) | | 2 | Priapism (a persistent, painful erection) | | 3 | Headache | | 4 | Hypotension | | 5 | Nausea | | 6 | Dizziness | | 7 | Bleeding at injection site | | 8 | Blood clot formation at injection site | | 9 | Pain or discomfort at the insertion site of the suppository | | 10 | Swelling at injection site | | 11 | Local skin reactions (erythema, edema, etc.) |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity to alprostadil or any of the excipients | | 2 | Severe cardiovascular conditions | | 3 | Severe bleeding disorders | | 4 | Conditions that could increase the risk of priapism | | 5 | Known anatomic conditions affecting the penis that could increase the risk of complications from injection |
|
| interactions | May interact with other medications that affect blood pressure or cardiovascular function, require careful monitoring by a healthcare professional. |
| warnings precautions | | 1 | Use only as prescribed by a healthcare professional. | | 2 | Close monitoring of the patient's response to treatment is crucial. | | 3 | Proper technique is essential in injection administration. | | 4 | Patients should be informed of the potential risks and side effects, especially the potential for priapism. | | 5 | Patients should understand that the medication is intended for localized use and not for systemic effects. |
|
| additional information | | 1 | Individualized dosing is crucial. Start low and titrate up based on the patient's response. | | 2 | Detailed instructions on injection technique must be provided to the patient by a qualified healthcare professional. |
|
| disclaimer | This information is for educational purposes only and does not constitute medical advice. Consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment. |
